A214390 logo

Kyongbo Pharmaceutical Co., Ltd Stock Price

KOSE:A214390 Community·₩162.6b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

A214390 Share Price Performance

₩0
-5440.00 (-100.00%)
₩0
-5440.00 (-100.00%)
Price ₩0

A214390 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Slight risk and slightly overvalued.

4 Risks
0 Rewards

Kyongbo Pharmaceutical Co., Ltd Key Details

₩264.1b

Revenue

₩161.8b

Cost of Revenue

₩102.3b

Gross Profit

₩102.1b

Other Expenses

₩182.3m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
7.63
38.74%
0.069%
86.0%
View Full Analysis

About A214390

Founded
1987
Employees
n/a
CEO
Tae-Young Kim
WebsiteView website
www.kbpharma.co.kr

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE. In addition, the company is involved in CDMO business; and research and development of Clopidogrel cardiovascular drug, Imatinlb anticancer drug, Donepezil anti-psychotic drug, Entecavir for anti-virus and infectious disease, and Esomeprazole. It also exports its products. The company was formerly known as Kyongbo Chemical Co. Ltd. and changed its name to Kyongbo Pharmaceutical Co., Ltd in March 2002. Kyongbo Pharmaceutical Co., Ltd was founded in 1987 and is headquartered in Asan-si, South Korea.

Recent A214390 News & Updates

Recent updates

No updates